SynopsisSwedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. The global Swedish Porphyria Drugs market size.....
SynopsisSwedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. The global Swedish Porphyria Treatment market .....
SynopsisSwedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. The global Swedish Porphyria Therapeutics mark.....
SynopsisNelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Nelarabine market size is expected to reach US$ 146.3 million by 2029, growing at a CAGR of 1.1% from 2023 to 2029. The market is mainly driven by the significant a.....
SynopsisArranon is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Arranon market size is expected to reach US$ 85 million by 2029, growing at a CAGR of 1.2% from 2023 to 2029. The market is mainly driven by the significant applicatio.....
SynopsisAtriance is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Atriance market size is expected to reach US$ 62 million by 2029, growing at a CAGR of 1.1% from 2023 to 2029. The market is mainly driven by the significant applicat.....
SynopsisInotuzumab ozogamicin is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The global Inotuzumab Ozogamicin market size is expected to reach US$ 405.9 million by 2029, growing at a CAGR o.....
SynopsisBesponsa is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The global Besponsa market size is expected to reach US$ 405.9 million by 2029, growing at a CAGR of 7.5% from 2023 to 2029. .....
SynopsisEnasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test The global Enasidenib market si.....
SynopsisEnasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test The global Enasidenib Drugs mar.....
